These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 25977991)
1. Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. Hatta FH; Lundblad M; Ramsjo M; Kang JH; Roh HK; Bertilsson L; Eliasson E; Aklillu E OMICS; 2015 Jun; 19(6):346-53. PubMed ID: 25977991 [TBL] [Abstract][Full Text] [Related]
2. P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects. Hatta FH; Aklillu E OMICS; 2015 Dec; 19(12):777-81. PubMed ID: 26669712 [TBL] [Abstract][Full Text] [Related]
3. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine? de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029 [TBL] [Abstract][Full Text] [Related]
4. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. Djordjevic N; Carrillo JA; van den Broek MP; Kishikawa J; Roh HK; Bertilsson L; Aklillu E Drug Metab Pharmacokinet; 2013; 28(2):93-7. PubMed ID: 22850738 [TBL] [Abstract][Full Text] [Related]
5. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. Hatta FH; Teh LK; Helldén A; Hellgren KE; Roh HK; Salleh MZ; Aklillu E; Bertilsson L Eur J Clin Pharmacol; 2012 Jul; 68(7):1033-42. PubMed ID: 22294058 [TBL] [Abstract][Full Text] [Related]
6. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Ghotbi R; Christensen M; Roh HK; Ingelman-Sundberg M; Aklillu E; Bertilsson L Eur J Clin Pharmacol; 2007 Jun; 63(6):537-46. PubMed ID: 17370067 [TBL] [Abstract][Full Text] [Related]
7. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement. Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104 [TBL] [Abstract][Full Text] [Related]
8. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. Vogl S; Lutz RW; Schönfelder G; Lutz WK PLoS One; 2015; 10(3):e0120403. PubMed ID: 25775139 [TBL] [Abstract][Full Text] [Related]
9. Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation? Goktaş MT; Hatta F; Karaca O; Kalkisim S; Kilic L; Akdogan A; Babaoglu MO; Bozkurt A; Helldén A; Bertilsson L; Yasar U Eur J Clin Pharmacol; 2015 Oct; 71(10):1223-8. PubMed ID: 26233334 [TBL] [Abstract][Full Text] [Related]
10. Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. Djordjevic N; Carrillo JA; Roh HK; Karlsson S; Ueda N; Bertilsson L; Aklillu E J Clin Pharmacol; 2012 Oct; 52(10):1527-34. PubMed ID: 22105431 [TBL] [Abstract][Full Text] [Related]
11. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Ramsjö M; Aklillu E; Bohman L; Ingelman-Sundberg M; Roh HK; Bertilsson L Eur J Clin Pharmacol; 2010 Sep; 66(9):871-7. PubMed ID: 20499227 [TBL] [Abstract][Full Text] [Related]
13. Relevance of CYP2C9 Function in Valproate Therapy. Monostory K; Nagy A; Tóth K; Bűdi T; Kiss Á; Déri M; Csukly G Curr Neuropharmacol; 2019; 17(1):99-106. PubMed ID: 29119932 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance. Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175 [TBL] [Abstract][Full Text] [Related]
15. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Céspedes-Garro C; Fricke-Galindo I; Naranjo ME; Rodrigues-Soares F; Fariñas H; de Andrés F; López-López M; Peñas-Lledó EM; LLerena A Expert Opin Drug Metab Toxicol; 2015; 11(12):1893-905. PubMed ID: 26595139 [TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis. De T; Christopher R; Nagaraja D Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212 [TBL] [Abstract][Full Text] [Related]
17. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. De Andrés F; Terán S; Hernández F; Terán E; LLerena A OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442 [TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363 [TBL] [Abstract][Full Text] [Related]
19. Functional characterization of 32 CYP2C9 allelic variants. Niinuma Y; Saito T; Takahashi M; Tsukada C; Ito M; Hirasawa N; Hiratsuka M Pharmacogenomics J; 2014 Apr; 14(2):107-14. PubMed ID: 23752738 [TBL] [Abstract][Full Text] [Related]
20. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Llerena A; Alvarez M; Dorado P; González I; Peñas-LLedó E; Pérez B; Cobaleda J; Calzadilla LR Pharmacogenomics J; 2014 Jun; 14(3):229-34. PubMed ID: 23959274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]